In the effort to engineer the immune system to fight cancer, researchers have encountered a recurring, lethal obstacle: the "friendly fire" of therapeutic cells. Known as fratricide, this phenomenon occurs when a treatment—whether a Chimeric Antigen Receptor (CAR) T cell or a monoclonal antibody—cannot distinguish between its intended target and the very immune cells meant to deliver the cure.
The Identity Crisis of Targeted Therapy
The fundamental challenge of immunotherapy is specificity. Most markers used to identify cancer cells are not exclusive to tumors; they are often shared by the healthy immune cells that are being recruited to fight the disease.
As Xiaomin Zhang and colleagues explain in CAR-T cell therapy in multiple myeloma: Current limitations and potential strategies, when a CAR-T cell is engineered to target a marker expressed on its own surface, the population undergoes a "self-targeting" phase. Instead of expanding to attack the tumor, the cells engage in mutual destruction. This is particularly problematic in T-cell malignancies. For instance, Meilan Zhang notes that targeting CD5—a marker found on both malignant and healthy T cells—leads to massive fratricide, hindering the manufacturing and persistence of the therapy (Case report: Differential diagnosis of highly amplified anti-CD5 CAR T cells...).
Activation as a Trigger for Self-Destruction
Fratricide is not always a result of static marker expression; sometimes, the act of fighting itself makes the immune cell a target. Le Qin demonstrated this paradox in Chimeric antigen receptor T cells targeting PD-L1 suppress tumor growth. While PD-L1 is a "shield" used by tumors to evade the immune system, T cells naturally upregulate PD-L1 when they become activated. Consequently, CAR-T cells designed to strip away the tumor's shield end up eliminating their own activated comrades, severely limiting the efficacy of combination therapies.
This "therapeutic fratricide" extends to innate immune cells as well. Guangbing Zhang points out that current anti-CD38 therapies for multiple myeloma often deplete the patient's natural killer (NK) cells because those cells also express CD38 (FTL004, an anti-CD38 mAb...).
Structural Sabotage: The Antibody Bridge
Fratricide can also be mediated by the physical structure of the drugs themselves. In The binding of an anti-PD-1 antibody to FcγRΙ has a profound impact on its biological functions, Xiaomin Song describes how the "tail" (Fc region) of an antibody can sabotage its "head."
If an anti-PD-1 antibody binds its target on a T cell while its Fc region simultaneously binds a receptor on a macrophage, it creates a physical bridge. This crosslinking triggers antibody-dependent cellular phagocytosis (ADCP), where the macrophage consumes the T cell. Instead of activating the T cell to fight cancer, the antibody inadvertently marks it for consumption by the body's own "garbage collectors."
An Evolutionary Trade-off
This risk of self-destruction is not a unique byproduct of modern medicine; it is a fundamental constraint of biological defense. Jakob Ruess and Gasper Tkacik argue in Molecular noise of innate immunity shapes bacteria-phage ecologies that even bacteria face this "self-restriction."
Bacterial immune enzymes must distinguish between foreign phage DNA and the host's own genetic material. If the protective marking of host DNA fails—even slightly—the immune system accidentally destroys the cell. This "molecular noise" creates a trade-off: a more aggressive immune system provides better protection against invaders but carries a higher risk of accidental suicide.
Engineering Around the Problem
To overcome fratricide, researchers are moving toward "masking" or "editing" the therapeutic cells.
- Gene Editing: Yao Wang and colleagues used CRISPR to knock out the CD33 gene in NK cells. By removing the target from the therapeutic cells themselves, they created "fratricide-resistant" cells that could effectively target leukemia without attacking one another (CD33 KO -CD33-mesothelin Loop CAR design...).
- Natural Selection: In some cases, the manufacturing process itself can be used to filter out vulnerable cells. Xuan Liu describes using "naturally selected" CD7 CAR-T cells, where the cells that survive the expansion phase are those that have naturally downregulated the target antigen, effectively bypassing the need for complex gene editing (Naturally selected CD7-directed CAR-T bridging allo-HSCT...).
By understanding fratricide as a predictable consequence of shared molecular markers and immune activation, researchers are developing a new generation of "armored" therapies that can distinguish between the enemy and the self.